For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites

A phase I trial evaluated the safety and efficacy of adding  lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.   Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However, TNBC readily becomes resistant to chemotherapy, and those with TNBC are more likely to have a recurrence or die within five years compared to those with other breast cancer types. Therefore, there is a need for safer and more effective TNBC treatments to improve patient outc...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conditions:   Solid Tumor;   Gastric Cancer;   Breast Cancer;   Ovarian Cancer;   Sarcoma Intervention:   Biological: CCT303-406 Sponsors:   Shanghai PerHum Therapeutics Co., Ltd.;   Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Solid Tumor;   Metastatic Cancer;   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER-2 Protein Overexpression;   Esophageal Cancer;   Ovarian Cancer;   Endometrium Cancer;   Bladder Cancer;   Pancreatic Cancer;   Colorectal Cancer;   Non Smal l Cell Lung Cancer;   EGF-R Positive Non-Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Triple Negati...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | HER2 | Sarcomas